Katerine Van Rietschoten

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.

This study discovers and optimizes bicyclic peptide inhibitors of E. coli PBP3, showing high-affinity binding and broad-spectrum antimicrobial activity.